GNOME: Cost effectiveness of intra-nasal steroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care
|Funding:||NIHR Health Technology Assessment programme (HTA)|
|Collaborators:||Dr. Ian Williamson and Dr. Sarah Benge, University of Southampton|
|Information:||Stavros Petrou and Helen Dakin|
Otitis media with effusion is a common condition in childhood, and in its chronic and recurrent forms a source of substantial NHS costs, with over £200 million per year spent on related prescribing. The majority of children are referred on from primary care, but confusions over treatment and uncertain diagnosis have historically contributed to a broad and at times inequitable gateway to secondary services. GNOME is a randomised controlled placebo-controlled trial evaluating topical intra-nasal steroids in 4-11 year old children with persistent bilateral otitis media with effusion, in primary care. HERC estimated the cost-effectiveness of the treatment over the nine month follow-up period of the trial. The application of multi-attribute utility measures within the trial has also allowed us to address important methodological issues around utility measurement in childhood, such as mapping between the disease-specific OM8-30 questionnaire and multi-attribute utility measures.
The results of the GNOME study have been published as a Health Technology Assessment report. In addition, the results of the economic evaluation have been published in Value in Health, clinical results have been published in the British Medical Journal and a separate study that maps between the OM8-30 health related quality of life measure and HUI has been published in Quality of Life Research.
Petrou, S, Dakin, H, Abangma, G, Benge, S, and Williamson, I (In Press). Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial Value in Health.
Dakin, H, Petrou, S, Haggard, M, Benge, S, and Williamson, I (2010). Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.Qual Life Res, 19(1):65-80.
Williamson, I, Benge, S, Barton, S, Petrou, S, Letley, L, Fasey, N, Haggard, M, and Little, P. 2009. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: a double blind randomised placebo controlled trial. British Medical Journal; 339:b4984, doi: 10.1136/bmj.b4984
Williamson, I, Benge, S, Petrou, S, Letley, L, Fasey, N, Abangma, G, Dakin, H, and Little, P. 2009. A double-blind randomised placebo controlled trial of topical intra-nasal corticosteroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion in primary care Health Technology Assessment. 13(37):1-144.